Multani Pratik S
Known title: Chief Medical OfficerCIK: 0001586894
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Erasca Faces Verastem Competition Amid Clinical Updates. Recent analysis highlights that Verastem's upcoming clinical data and commercial launch present a competitive challenge for Erasca. While Erasca's Revolution approval has reduced some development risk, the market is watching how the company navigates this new competitive landscape. The stock currently trades near significant support levels, reflecting cautious sentiment as investors assess these developments.
Transaction History
| ORIC | ▼ Sell | Open Market | 10,720 | $97K | 12/16/2025 | View on chart |
| ORIC | ▲ Buy | Option Exercise | 29,333 | $0 | 12/15/2025 | View on chart |
| ERAS | ▼ Sell | Gift | 6,200 | $0 | 5/23/2025 | View on chart |
| ERAS | ▼ Sell | Gift | 6,200 | $0 | 5/23/2025 | View on chart |
| ORIC | ▼ Sell | Open Market | 8,850 | $73K | 12/16/2024 | View on chart |
| ORIC | ▲ Buy | Option Exercise | 24,042 | $0 | 12/15/2024 | View on chart |
| ORIC | ▲ Buy | Option Exercise | 14,042 | $0 | 12/15/2023 | View on chart |
| ORIC | ▼ Sell | Open Market | 5,282 | $45K | 12/15/2023 | View on chart |
| ORIC | ▲ Buy | Option Exercise | 6,041 | $0 | 12/15/2022 | View on chart |
| ORIC | ▼ Sell | Open Market | 2,089 | $7K | 12/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
JP Morgan Upgrades ORIC, Raises Target to $26
JP Morgan has upgraded ORIC to Overweight and lifted its price target to $26, reflecting confidence in the company’s pipeline. A recent Yahoo article questions whether ORIC’s off‑balance‑sheet funding for project ORIC‑259 changes its R&D risk profile. These developments add new context to the stock’s current technical position near its 200‑day SMA and a support level of $8.69.
JP Morgan Upgrades ORIC, Raises Target to $26. JP Morgan has upgraded ORIC to Overweight and lifted its price target to $26, reflecting confidence in the company’s pipeline. A recent Yahoo article questions whether ORIC’s off‑balance‑sheet funding for project ORIC‑259 changes its R&D risk profile. These developments add new context to the stock’s current technical position near its 200‑day SMA and a support level of $8.69.